Advertisement
Screener

Savara Inc (SVRA) Graph

SVRA Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development (m); Selling, general and administrative (m); Operating expenses $40.97M.
  • 2026-03-31: Revenue (m); Research and development (m); Selling, general and administrative (m); Operating expenses $38.99M.
  • 2025-12-31: Revenue (m); Research and development (m); Selling, general and administrative (m); Operating expenses $33.42M*.
  • 2025-09-30: Revenue (m); Research and development (m); Selling, general and administrative (m); Operating expenses $30.25M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30(m)(m)(m)$40.97M(m)-$40.23M
2026-03-31(m)(m)(m)$38.99M(m)-$37.28M
2025-12-31(m)(m)(m)$33.42M*(m)-$32.24M*
2025-09-30(m)(m)(m)$30.25M(m)-$29.56M
2025-06-30(m)(m)(m)$31.44M(m)-$30.40M
2025-03-31(m)(m)(m)$28.43M(m)-$26.64M
2024-09-30(m)(m)(m)$26.36M(m)-$24.25M
2024-06-30(m)(m)(m)$23.19M(m)-$22.24M
2024-03-31(m)(m)(m)$22.48M(m)-$20.35M
2023-09-30(m)(m)(m)$18.04M(m)-$16.60M
2023-06-30(m)(m)(m)$12.22M(m)-$11.44M
2023-03-31(m)(m)(m)$12.11M(m)-$10.56M
2022-09-30(m)(m)(m)$10.54M(m)-$10.39M
2022-06-30(m)(m)(m)$9.38M(m)-$9.16M
2022-03-31(m)(m)(m)$8.05M(m)-$8.30M
2021-09-30$0.00(m)(m)$9.97M(m)-$10.55M
2021-06-30(m)(m)(m)$10.45M(m)-$10.94M
2021-03-31(m)(m)(m)$10.41M(m)-$10.22M
2020-09-30$256.00K(m)(m)$11.04M(m)-$11.06M
2020-06-30(m)(m)(m)$9.26M(m)-$9.39M
2020-03-31$0.00(m)(m)$16.24M(m)-$15.42M
2019-12-31$0.00*(m)(m)(m)(m)-$31.72M
2019-09-30(m)(m)(m)$12.44M(m)-$12.40M
2019-06-30(m)(m)(m)$22.15M(m)-$21.94M
2019-03-31$0.00$1.40M(m)$12.92M(m)-$12.11M
2018-12-31(m)(m)(m)(m)$2.50M-$10.51M
2018-09-30(m)(m)(m)$12.78M-$110.00K-$12.56M
2018-06-30(m)(m)(m)$11.91M-$277.00K-$11.59M
2018-03-31(m)(m)(m)$32.11M-$4.55M-$26.85M
2017-12-31(m)(m)(m)(m)(m)-$6.50M
2017-09-30(m)(m)(m)$6.54M-$117.00K-$6.82M
2017-06-30(m)(m)(m)$9.34M-$470.00K-$11.50M
2017-03-31$94.00K(m)$1.58M$4.77M-$237.00K-$4.97M
2016-12-31$400.00K(m)$1.93M*(m)(m)-$3.97M
2016-09-30$45.00K(m)$2.13M$3.23M(m)-$3.23M
2016-06-30$0.00(m)$2.44M$1.98M(m)-$2.05M
2016-03-31$0.00(m)$2.83M$10.74M(m)-$1.68M
2015-12-31(m)(m)(m)(m)(m)-$10.16M
2015-09-30$0.00(m)$2.46M$9.83M(m)-$9.91M
2015-06-30$0.00(m)$2.41M$10.18M(m)-$10.15M
2015-03-31$0.00(m)$3.58M$9.65M(m)-$9.62M
2014-12-31(m)(m)(m)(m)(m)-$7.31M
2014-09-30$0.00(m)$2.46M$7.88M(m)-$7.87M
2014-06-30$0.00(m)$2.37M$7.20M(m)-$7.15M
2014-03-31$0.00(m)$2.27M$6.84M(m)-$6.37M
2013-12-31(m)(m)(m)(m)(m)-$5.71M
2013-09-30$0.00(m)$2.16M$5.27M(m)-$5.25M
2013-06-30(m)(m)$2.10M$4.95M(m)-$4.94M
2013-03-31(m)(m)$2.11M$5.59M(m)-$5.58M
2012-12-31(m)(m)(m)(m)(m)-$4.00M
2012-09-30(m)(m)$1.82M$3.22M(m)-$3.20M
2012-06-30(m)(m)$1.87M$4.22M(m)-$4.21M
2012-03-31(m)(m)$2.05M$4.17M(m)-$4.15M
2011-12-31(m)(m)(m)(m)(m)-$2.37M
2011-09-30(m)(m)$1.98M$3.55M(m)-$3.54M
2011-06-30(m)(m)$1.82M$4.41M(m)-$4.39M
2011-03-31(m)(m)$1.57M$2.99M(m)-$2.96M
2010-09-30(m)(m)$944.95K$1.87M(m)-$1.84M
2010-06-30(m)(m)$1.30M$1.94M(m)-$1.92M

Revenue and expense 6 month

Period endRevenueSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30(m)(m)$79.95M(m)-$77.51M
2025-06-30(m)(m)$59.87M(m)-$57.04M
2024-06-30(m)(m)$45.66M(m)-$42.59M
2023-06-30(m)(m)$24.33M(m)-$22.00M
2022-06-30(m)(m)$17.43M(m)-$17.46M
2021-06-30(m)(m)$20.87M(m)-$21.16M
2020-06-30$0.00(m)$25.50M(m)-$24.81M
2019-06-30$0.00(m)$35.07M(m)-$34.05M
2018-06-30(m)(m)$44.01M-$4.55M-$38.44M
2017-06-30(m)(m)$14.22M-$707.00K-$16.48M
2016-06-30$0.00$5.27M$3.67M(m)-$3.73M
2015-06-30$0.00$5.99M$19.83M(m)-$19.77M
2014-06-30$0.00$4.64M$14.04M(m)-$13.52M
2013-06-30(m)$4.21M$10.55M(m)-$10.52M
2012-06-30(m)$3.92M$8.39M(m)-$8.36M
2011-06-30(m)$3.40M$7.40M(m)-$7.35M
2010-06-30(m)$2.48M$4.36M(m)-$4.32M

Revenue and expense 7 month

Period endNet income
1996-12-31-$259.48K

Revenue and expense 9 month

Period endRevenueSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30(m)(m)$90.13M(m)-$86.60M
2024-09-30(m)(m)$72.02M(m)-$66.84M
2023-09-30(m)(m)$42.38M(m)-$38.60M
2022-09-30(m)(m)$27.96M(m)-$27.85M
2021-09-30$0.00(m)$30.84M(m)-$31.70M
2020-09-30$256.00K(m)$36.54M(m)-$35.87M
2019-09-30$0.00(m)$47.52M(m)-$46.45M
2018-09-30(m)(m)$56.80M-$4.55M-$51.00M
2017-09-30(m)(m)$20.76M-$824.00K-$23.29M
2016-09-30$45.00K$7.41M$6.91M(m)-$6.96M
2015-09-30$0.00$8.45M$29.66M(m)-$29.68M
2014-09-30$0.00$7.09M$21.93M(m)-$21.39M
2013-09-30$0.00$6.37M$15.82M(m)-$15.78M
2012-09-30(m)$5.73M$11.61M(m)-$11.56M
2011-09-30(m)$5.38M$10.95M(m)-$10.89M
2010-09-30(m)$3.42M$6.23M(m)-$6.17M

Revenue and expense 12 month

Period endRevenueSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31(m)(m)$123.55M$0.00-$118.84M
2024-12-31(m)(m)$103.20M$9.00K-$95.88M
2023-12-31(m)(m)$60.01M(m)-$54.70M
2022-12-31(m)(m)$38.84M(m)-$38.15M
2021-12-31(m)(m)$41.48M(m)-$43.01M
2020-12-31$257.00K(m)$49.56M(m)-$49.62M
2019-12-31$0.00(m)$79.03M(m)-$78.17M
2018-12-31(m)(m)$70.05M-$7.06M-$61.52M
2017-12-31$0.00(m)$29.96M-$3.63M-$29.80M
2016-12-31$400.00K$9.34M$11.35M-$357.00K-$10.92M
2015-12-31$54.00K$10.96M$5.98M$0.00-$9.00M
2014-12-31$0.00$9.49M$29.28M$0.00-$28.70M
2013-12-31$0.00$8.52M$21.54M$0.00-$21.48M
2012-12-31$0.00$7.52M$15.63M(m)-$15.56M
2011-12-31(m)$7.19M$13.40M(m)-$13.26M
2010-12-31$488.96K$4.99M$9.03M(m)-$8.45M
2009-12-31(m)(m)(m)(m)-$11.33M
2008-12-31(m)(m)(m)(m)-$26.65M
2007-12-31(m)(m)(m)(m)-$22.14M
2006-12-31(m)(m)(m)(m)-$29.33M
2005-12-31(m)(m)(m)(m)-$24.78M
2004-12-31(m)(m)(m)(m)-$6.70M
2003-12-31(m)(m)(m)(m)-$2.33M
2002-12-31(m)(m)(m)(m)-$2.11M
2001-12-31(m)(m)(m)(m)-$16.34M
2000-12-31(m)(m)(m)(m)-$3.70M
1999-12-31(m)(m)(m)(m)-$1.06M
1998-12-31(m)(m)(m)(m)-$1.20M
1997-12-31(m)(m)(m)(m)-$1.98M

Similar stocks

Stock NameCountryMarket CapPE Ratio
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
MANNKIND CORP (MNKD)United States$1.058B-30.41
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19
Seaport Therapeutics, Inc. (SPTX)United States$1.131B